Granules India Q4 FY26 Earnings Call Transcript Released
Granules India reported FY26 revenue of INR 53,656 million, a 20% YoY increase. EBITDA grew 25% to INR 11,851 million, with margins at 22.1%. The peptide CDMO business generated INR 1,593 million revenue. Net debt reduced to INR 4,021 million. The company is focused on FDA readiness, complex products, and scaling CDMO operations.
The announcement provides a detailed transcript of the earnings call, which includes comprehensive financial and operational updates. While positive, it does not introduce new, material events or guidance that would drastically alter the company's valuation or strategic outlook beyond what was already anticipated or discussed in the earnings release itself.
The company reported strong financial performance with significant revenue and EBITDA growth, a reduction in net debt, and positive developments in its strategic initiatives like the peptide CDMO business. The commentary from management also reflects confidence in future growth and stability.
Granules India Limited has released the transcript of its earnings conference call for the fourth quarter and the financial year ended March 31, 2026. The call, which took place on April 29, 2026, featured discussions on the company's performance, strategic progress, and future outlook.
Dr. Krishna Prasad Chigurupati, Chairman and Managing Director, highlighted that FY26 was a year of "deliberate reset and measurable progress," with stabilized performance, strengthened execution, and clear strategic choices for sustainable growth. The GPI facility in Virginia reached its operating potential, and the acquisition of Senn validated the investment thesis in the CDMO segment, turning EBITDA positive within the third quarter post-acquisition. The company also accelerated its shift towards more complex and differentiated products.
Financially, FY26 saw revenue grow by 20% year-on-year to INR 53,656 million. The finished dosages business contributed 74% of revenue, with Europe showing strong growth of 81% year-on-year. The peptide CDMO business emerged as a fourth revenue pillar, generating INR 1,593 million in FY26 revenue and delivering positive EBITDA in Q4. EBITDA for FY26 stood at INR 11,851 million, up 25% year-on-year, with margins expanding to 22.1%. Net debt reduced to INR 4,021 million from INR 7,061 million in FY25.
Quality and compliance remained key priorities, with remediation activities progressing at the Gagillapur facility. The company successfully completed regulatory inspections across key sites, including receiving an EIR with VAI status for the GLS facility and zero observations for the GCH facility. Investments in digital quality infrastructure are enhancing compliance rigor.
Looking ahead to FY27, the focus remains on achieving sustained U.S. FDA readiness in Gagillapur, scaling commercial contributions from GLS, accelerating the shift towards complex products, and maintaining disciplined capital allocation. The company is also preparing for potential U.S. product launches.
The transcript also detailed progress on the peptide CDMO platform, including the return to positive EBITDA performance for Senn Chemicals and plans for infrastructure upgrades and future peptide API capacity in India. The company is projecting PAT positive performance on an annual basis for FY27 for the peptide CDMO business.
What to do with a filing like this
Granules India Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Granules India Limited. Read the original for the full detail.